Industry analyst GlobalData has outlined the driving factors in hematology, identifying Ultomiris (ravulizumab), Hemlibra (emicizumab) and Vafseo (vadadustat) as key products in this category.
There has been a significant increase in revenues for hematology products in recent periods, making this the fastest-growing therapy area for the second year running.
Alexion Pharmaceuticals’ Ultomiris, Genentech’s Hemlibra, and Akebia Therapeutics’ (Nasdaq: AKBA) Vafseo (vadadustat) are likely to be responsible for much of the growth going forward.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze